Argininosuccinic acidemia

Neurogenetic Disorders

Updated 08.06.2024
Released 04.24.1995
Expires For CME 08.06.2027

Argininosuccinic acidemia

Authors: Stefan Kolker MD, Matthias Zielonka MD

See Contributor Disclosures

Editor: Barry Wolf MD PhD

Argininosuccinic acidemia

In This Article

Quick Link

Introduction

Overview

Argininosuccinic aciduria is an inherited urea cycle disorder caused by argininosuccinic acid lyase deficiency. Patients can present with hyperammonemic encephalopathy at any age, resulting in brain damage or even death if treatment is inadequate or delayed. Patients may also develop hepatomegaly, progressive liver fibrosis, and liver function abnormalities, but they can also present with intellectual disabilities only. The disease can be detected by tandem mass spectrometry-based newborn screening. Treatment consists of low-protein diet, nitrogen scavengers, and L-arginine. Liver transplantation prevents the production of toxic metabolites in the liver, but not in nonhepatic tissues. The authors discuss a model that helps to predict the putative disease severity of asymptomatic individuals identified by newborn screening. Furthermore, they discuss a recently discovered mechanism that links argininosuccinic acid lyase deficiency with decreased cerebral catecholamine synthesis, elevated alpha-synuclein, seizure activity, and neurologic deficits.

Historical note and terminology

Argininosuccinic acidemia was first described in 1958 by Allan and colleagues (02). Its name derives from the marked elevation of argininosuccinic acid in blood of affected individuals. This disorder has also been called argininosuccinic aciduria because of the increased excretion of argininosuccinic acid in urine, and argininosuccinate lyase deficiency to denote its enzyme deficiency.

Clinical manifestations

Presentation and course

The classic presentation of argininosuccinic acidemia is as a catastrophic illness in the first week of life. Typically, the affected neonate is born after an uncomplicated full-term pregnancy with normal labor, delivery, and Apgar scores. Clinical symptoms develop in the first week of life as “poor suck,” hypotonia, vomiting, lethargy, and hyperventilation, progressing to coma (18). During hyperammonemic coma, increased intracranial pressure with neurologic findings, including increased deep tendon reflexes, papilledema, and decorticate or decerebrate posturing are usually found. Seizures are a late complication and follow alterations in consciousness. Epileptiform activity consists mainly of multiareal spikes, spike-waves, or sharp-and-slow-wave activity. There may also be sustained monorhythmic theta activity (74).

Cases of childhood-onset disease with a partial enzyme deficiency have been reported (68). In these cases, symptoms generally develop later in childhood and include anorexia and food intolerance, developmental delay, and behavioral changes (32). Hyperammonemic crises in affected individuals have been precipitated by high-protein meals, viral infections, medication (eg, valproate), trauma, anesthesia (05), and surgery (54). Late-onset patients are being increasingly reported in current publications. They may have been underreported previously. Late-onset patients who never develop hyperammonemic crises, but predominantly present with intellectual disability or other neurologic symptoms, often remain undiagnosed for months or years (37). In addition, patients with a putatively benign phenotype have been identified by newborn screening, demonstrating the clinical variability of this disease (78; 52).

In addition to hyperammonemic coma in the newborn period and recurrent hyperammonemic episodes later in childhood, affected children develop a specific abnormality of the hair termed "trichorrhexis nodosa." Nodules appear on the hair shaft and the hair is friable. A generalized erythematous maculopapular skin rash may also appear in this disorder. Both conditions are associated with arginine deficiency and respond to arginine supplementation (19). Chronic hepatomegaly (8 to 10 cm below the costal margin) has been reported, both in patients treated with protein restriction and in those receiving arginine supplementation. Pathologic examination shows modest fatty infiltration and fibrosis. Liver function tests can be normal in some patients except during hyperammonemic crises (84), but in other patients, are chronically and progressively abnormal. Liver abnormalities are observed mainly in patients with the severe early-onset form of the disease (72). Hypertension due to impaired systemic nitric oxide (NO) production may be an underrecognized feature of this disease (66; 15). Hypertension was shown to respond dramatically to treatment with an organic nitrate (56). In a mouse model, argininosuccinic acidemia was lethal in the neonatal period and showed a biochemical phenotype identical to the human disease (64).

Grioni and colleagues reported that 6 of 11 patients with argininosuccinic acidemia developed epilepsy following a seizure-free interval after onset of the disease (28). Abnormal neuroimaging findings in argininosuccinic aciduria are frequent and consist of parenchymal infarcts, focal white matter hyperintensity, cortical or cerebral atrophy, and nodular hypertopia. Although proton spectroscopy of basal ganglia indicated a significant decrease of N-acetylaspartate and choline in patients with early-onset disease, spectroscopy of white matter was characterized by a concomitant decrease of creatine and increased concentrations of guanidinoacetate in both early- and late-onset patients (11).

An international study on urea cycle disorders demonstrated that some adolescent and adult patients developed chronic renal failure (39). Because the onset of chronic renal failure does not correlate with the severity of neurologic symptoms in this cohort, different pathomechanisms should be considered for renal and neurologic disease manifestations. This notion is supported by a longitudinal study performed by Baruteau and colleagues, who investigated frequency and pattern of neurologic and systemic disease manifestations in a cohort of 56 patients. Extra-neurologic symptoms, including persistent rise in plasma alanine aminotransferase activity usually associated with hepatomegaly, transient or persistent hypokalemia, and chronic diarrhea, were more frequent in patients with an early-onset as opposed to the late-onset or screened cohort. In contrast, the pattern and severity of the neurologic phenotype was equally distributed between the early- and late-onset group and did not correlate with the severity of hyperammonemia and plasma argininosuccinic acid concentrations, implicating alternative underlying pathomechanisms (eg, cerebral NO-deficiency, secondary creatine deficiency) for the neurologic impairment in argininosuccinic aciduria (11).

Prognosis and complications

Prior to the development of alternate pathway therapy, virtually all children with neonatal-onset argininosuccinic acidemia died in infancy (69). Most died in the newborn period, and the remainder succumbed to intercurrent hyperammonemic episodes or protein malnutrition. Although a significant number of neonates may still succumb during neonatal hyperammonemic coma (12), patients with argininosuccinate lyase deficiency have the lowest risk of neonatal mortality among all urea cycle disorders. A metaanalysis demonstrated that overall 91% of symptomatic patients with this disease survive the first year of life, whereas only 81% of patients with neonatal disease manifestation survive the neonatal period (20).

Although neonatal mortality has decreased, morbidity remains high in survivors of neonatal hyperammonemic coma. Over 75% have mental retardation, and there is frequently comorbidity with cerebral palsy, seizure disorder, and visual deficits (55; 73). There appears to be a correlation between intellectual function and duration of hyperammonemic coma. Children in neonatal hyperammonemic coma for less than 3 days have a far better outcome than those in coma for longer periods of time (55). Cognitive outcome also is better in prospectively treated infants with complete defects and in children with partial defects (47). However, increasing evidence has been gathered that neurologic disease is progressive over time with increasing frequency of cognitive impairment despite early therapeutic intervention (52; 01; 11).

Clinical vignette

A 17-month-old girl, the product of a 36-week gestation, was born to a gravida 1, para 2, 22-year-old mother. There was no consanguinity. The child breast fed normally until 60 hours of age, when she started to refuse feedings and became lethargic. Nevertheless, she was discharged on the third day of life. At home, she was difficult to arouse and had gasping respirations. At 90 hours of age, she had a seizure and a respiratory arrest. She was readmitted to the hospital, where she was intubated and treated for sepsis. She remained in stage IV coma, being unresponsive to painful stimuli. The plasma ammonium concentration, determined on the fifth day of life, was 500 µM. Plasma amino acids showed a large peak of argininosuccinic acid, and its 2 anhydrides and citrulline concentration was also elevated. The child was treated with peritoneal dialysis and intravenous arginine. The ammonium concentration fell to 250 µM within 4 hours of initiation of therapy. However, she did not recover from coma until 9 days of age. Computerized tomography of the brain showed a grade IV intraventricular hemorrhage. She was discharged at 2 months of age on a protein-restricted diet and arginine supplementation. The child subsequently developed myoclonic seizures and spastic quadriplegia. Cognitive development remained extremely delayed. She had no further hyperammonemic episodes until 17 months of age, when she developed vomiting and lethargy during an upper respiratory tract infection. The mother elected not to take her to the hospital, and she died at home.

Biological basis

Etiology and pathogenesis

Argininosuccinic acidemia is caused by a partial or complete deficiency of argininosuccinate lyase (EC 4.3.2.1), also called argininosuccinase, a cytosolic enzyme in the urea cycle that catalyzes the cleavage of argininosuccinic acid into arginine and fumarate (16). The majority of mutations are private and missense mutations (08).

Argininosuccinic acidemia is inherited as an autosomal recessive trait. The deficient enzyme is expressed in multiple tissues. The ASL gene is located on chromosome 7q11.21 (58; 71). The enzyme is a homotetramer of 50-kD subunits. There is evidence of multiple allelic mutations and intraallelic complementation in this disorder, indicating extensive genetic heterogeneity (75; 80; 08), however, some mutations appear at a higher frequency than others and may represent hot spots with higher susceptibility for alteration (46; 08). A founder mutation causing neonatal-onset disease has been found in patients from Saudi Arabia (03). Another founder mutation was identified in the Finnish population (08). The presence of cross-reacting material in all the mutants is consistent with expression of the mutant enzyme (09). The multiple mutations may account for the observed heterogeneity in this disease at the clinical level (31). Erez and colleagues demonstrated that argininosuccinate lyase is not only an enzyme with catalytic function that leads to arginine production by the urea cycle, but it is also part of a multi-protein complex that includes endothelial nitric oxide synthase and is critically important for systemic nitric oxide synthesis (26). Erez and colleagues also showed that dysfunction of the enzyme not only leads to endogenous arginine deficiency, but it hampers the ability of the cell to use extracellular arginine for nitric oxide synthesis. Because arterial hypertension is not frequently reported, it remains to be determined whether this complication is still underreported or whether impaired systemic nitric oxide production is restricted to patients with specific mutations.

Biochemically, the principal finding is hyperammonemia, argininosuccinic acidemia, and argininosuccinic aciduria. Plasma ammonium concentrations are 10- to 100-fold normal during hyperammonemic crisis, and the plasma argininosuccinic acid peak is large (normally undetectable) (14). It should be noted that this peak may be missed in the amino acid analysis, as it can overlie the peak for the essential amino acids leucine or isoleucine. However, the presence of the 2 anhydrides of argininosuccinic acid in areas of the chromatogram where homocystine and GABA are found, aids in the diagnosis. Argininosuccinic acid is also detectable by tandem mass spectrometry, and markedly increased argininosuccinic acid is readily identifiable in the urine. Other plasma amino acid abnormalities include 3-fold to 10-fold elevated concentrations of citrulline (100 to 300 µmol/L), elevated glutamine (a storage form of ammonia), and decreased arginine (the product of argininosuccinate lyase). Additionally, urinary orotic acid excretion can be increased (06). The diagnosis can be confirmed by measuring argininosuccinate lyase in erythrocytes or fibroblasts and by molecular genetic testing.

A model that predicts phenotypic severity in individuals with argininosuccinic acidemia has been developed, which integrates genotype-specific data with biochemical and clinical endpoints in affected individuals. In this model, residual enzymatic ASL activity not only correlates with the clinical severity of the hyperammonemic episode at initial manifestation, but also predicts the frequency and severity of future hyperammonemic decompensations and neurologic outcomes. This model highlights that in vitro residual enzyme activity is a robust biomarker that differentiates between severe (ASL activity < 8.7%) and attenuated phenotypes (ASL activity ≥8.7%) (82). In neonates dying of hyperammonemic coma, neuropathologic changes involve prominent cerebral edema and generalized neuronal cell loss (43). In survivors of prolonged neonatal hyperammonemic coma, changes observed on neuroimaging studies obtained months later include ventriculomegaly with increased sulcal markings, bilateral symmetrical low-density white matter defects, and diffuse atrophy with sparing of the cerebellum (55). Neuropathology in those children who subsequently died was consistent with the neuroimaging findings and included ulegyria, cortical atrophy with ventriculomegaly, and prominent cortical neuronal loss (53; 21).

The mechanism of the ammonia-induced brain damage remains unclear. Ammonia is physiologically detoxified in astrocytes by glutamate dehydrogenase and glutamine synthetase. The accumulation of ammonia and glutamine has a number of potentially toxic effects on the brain, including depletion of intermediates of cell energy metabolism and organic osmolytes, altered amino acid and neurotransmitter concentrations (eg, glutamate and GABA), increased extracellular potassium concentrations (32; 23; 13; 85; 22; 44; 81; 83; 63), potentially altered water transport through aquaporin 4 channels (44), and oxidative and nitrosative stress due to increased free radical production and increased nitric oxide synthesis (60). More than 1 mechanism is probably active. It is unclear whether argininosuccinic acid accumulation contributes to brain injury. Patients who have never had a hyperammonemic crisis can exhibit intellectual disability and seizures, thereby supporting this possibility (27; 25; 56). Further study is needed to determine the pathologic role of the elevated concentrations of argininosuccinic acid in the brains of patients with this disorder, especially because liver transplant does not fully correct the argininosuccinic acidemia and abnormalities in brain metabolism (66; 50; 59). It has been hypothesized that cerebral accumulation of argininosuccinate may be facilitated by limited efflux of di- and tricarboxylic acids across the blood-brain barrier causing intracerebral entrapment of these metabolites (38).

In addition to the potential neurotoxic effect of argininosuccinic acid, nitric oxide deficiency may be a cause of tissue damage in argininosuccinic acidemia. As mentioned, argininosuccinate lyase is thought to be part of a multi-protein complex that includes nitric oxide synthase and is critical for nitric oxide synthesis. Patients with argininosuccinic aciduria are deficient in arginine and NO production; deficient NO production can be another cause of the brain damage (26; 56). Cerebral nitrosative stress due to reactive nitrogen species has been demonstrated as an additional underlying cause of neurotoxicity in argininosuccinic aciduria (10). It has been shown that ASL deficiency is associated with decreased catecholamine synthesis due to impaired tyrosine hydroxylase activity in the nucleus locus coeruleus as well as dopaminergic neurons and the substantia nigra, which leads to the formation of tyrosine aggregates and an elevation of alpha-synuclein, thereby promoting abnormal stress response, seizure sensitivity, as well as motor and neurocognitive deficits (41; 42).

Liver enlargement and elevated liver enzyme in serum are frequently observed in neonatal-onset cases. Hepatic pathology studies show diffuse microvesicular steatosis, periportal nuclear glycogen, and variable portal fibrosis with occasional portal to portal bridging (07). The mechanism for liver damage is unclear and could potentially be caused by argininosuccinate or its derivatives. Anecdotal reports suggest that treatment with ammonia scavenging drugs reduce liver size and liver enzyme activities in serum in some patients.

A clinical trial of ammonia scavenger treatment combined with either low-dose arginine supplementation or high-dose arginine supplementation demonstrated benefit of an ammonia scavenger combined with low-dose arginine treatment in ameliorating liver damage (57).

Prevention

Argininosuccinic acid concentrations in amniotic fluid, as well as [¹⁴C]citrulline incorporation into proteins of chorionic villi, have been used for prenatal diagnosis in at-risk families (35; 49; 36). Preimplantation genetic diagnosis in couples at risk is now a possibility (30), and prenatal DNA diagnosis was made using a single fetal nucleated erythrocyte isolated from maternal blood (76). In affected families, prospective treatment of this disorder from birth has been associated with an improved outcome (24; 47). Newborn screening by tandem mass spectrometry using blood spots allows preclinical diagnosis of this condition and early treatment (04). However, it still remains to be elucidated whether newborn screening is beneficial for patients with argininosuccinic acidemia, especially with regard to cognitive function. Some patients may already present with a neonatal metabolic crisis before the results of newborn screening are available; other patients identified by newborn screening may have a benign disease course (52). The group of symptomatic individuals who initially exhibited symptoms after the newborn period, ie, the late-onset group, may derive the greatest benefit from newborn screening (61). A severity-adjusted analysis for the cytosolic urea cycle disorders, citrullinemia type 1 and argininosuccinic academia, demonstrated that early identification by newborn screening (and subsequent early implementation of therapy) resulted in reduced severity of the initial hyperammonemic episodes for individuals with severe and attenuated phenotypes (62). Intriguingly, the effect was most pronounced for the attenuated disease group because individuals identified by newborn screening exhibited plasma ammonium concentrations within the normal range (62).

Management

For a detailed discussion of treatment see the current published guidelines for urea cycle disorders (29).

Long-term treatment of argininosuccinic acidemia relies on the principles of restricting nitrogen intake and stimulating an alternate pathway for waste nitrogen excretion. Nitrogen restriction involves the use of a high-caloric, low-protein diet. The approach to stimulating an alternate pathway of waste nitrogen excretion involves the use of arginine supplementation (18). The rationale for using arginine is as follows. Argininosuccinic acid contains both waste nitrogen atoms destined for excretion as urea. Furthermore, it has a renal clearance rate equal to the glomerular filtration rate. Thus, provided it is continuously synthesized and excreted, argininosuccinic acid should serve as an efficient substitute for urea as a waste nitrogen product. However, deficient activity of argininosuccinate lyase prevents the synthesis of arginine, leading to decreased availability of ornithine for argininosuccinic acid synthesis. A solution would be to provide adequate arginine to prime the cycle. The new pathway for waste nitrogen excretion would then start at arginine and end in argininosuccinic acid excretion. For each mole of arginine given, 2 moles of waste nitrogen would be removed as argininosuccinic acid. Two to 4 moles/kg per day (0.4 to 0.7 g/kg per day) of L-arginine free base are thought to be sufficient to stabilize ammonium concentrations when combined with protein restriction (12). However, as mentioned above, 1 clinical trial has shown efficacy of phenylbutyrate treatment combined with low-dose arginine compared to the combined treatment with high-dose arginine in ameliorating liver damage (57). Therefore, the daily arginine dosage should not exceed 2 mmol/kg per day (29).

Theoretically, the efficacy of arginine supplementation may be limited by a relative deficiency in aspartate; this substance normally combines with citrulline to form argininosuccinic acid. It has been suggested that a supplement of citrate salt (2 mmol/kg per day) may prevent this from occurring by repletion of aspartate stores through the production of oxaloacetate (33; 65).

In some patients, occasionally additional alternate pathway therapy may be required; in particular with arginine supplementation, plasma arginine concentrations should be kept below 2 mmol/kg per day. Nitrogen scavengers, such as sodium benzoate and sodium or glycerol phenylbutyrate, are used for this purpose. Benzoate is a compound that is conjugated with glycine to form hippurate that is cleared by the kidney at 5-fold the glomerular filtration rate (40). Phenylacetate, which is formed from phenylbutyrate by the liver, conjugates with glutamine to form phenylacetylglutamine, a substance that is excreted by the kidney. Over 40% of total waste nitrogen can be excreted as phenylacetylglutamine (17). Commonly used starting doses are either 250 mg/kg per day (or 5 g/m2 per day) each of benzoate and phenylbutyrate (29); however, doses must be adjusted to the individual patient. In general, antiepileptic treatment with valproate should be avoided, if possible.

Enzyme replacement through liver transplantation has been attempted. In children with urea cycle defects who have received orthotopic liver transplants, the procedure has improved the metabolic abnormalities and permitted a normal protein intake in most patients (77; 50; 59). However, there have been reports of at least 2 deaths from graft-versus-host disease, and long-term immunosuppression is required in all patients. Most importantly, liver transplantation does not correct the defect in tissues other than liver.

Early identification and treatment of intercurrent hyperammonemic episodes is essential, both because treatment is more effective at lower ammonium concentrations and because neurologic outcome appears to be a function of duration of severe hyperammonemia (55). Anticipatory management of hyperammonemia is often feasible in a previously diagnosed case. Increases in ammonium concentrations have been found to lag by days to weeks behind elevations in glutamine (48). Therefore, periodic measurement of plasma amino acids (that include glutamine) and ammonium may permit adjustment of therapy before clinical symptoms appear. When the patient is asymptomatic and biochemical abnormalities are detected, the patient usually responds to lowering nitrogen intake or increasing the doses of ammonia scavenging agents.

If symptoms of vomiting and lethargy become evident and ammonium concentrations are increased, intermittent metabolic emergency treatment is indicated (29). This involves hospitalization with reduction or transiently complete elimination of protein and the intravenous administration of glucose-enriched saline, intravenous L-arginine-HCl, benzoate, and phenylacetate. In severe hyperammonemic encephalopathy, extracorporeal detoxification with hemofiltration/hemodialysis should be initiated rapidly. For details, please read the international recommendations for urea cycle disorders (29).

Cysteamine treatment in vitro increases the residual enzyme activity of transfected cells with cysteine for arginine mutations. Because 12% of all known pathogenic genetic variations of argininosuccinate lyase deficiency cause a cysteine for arginine change, it has been hypothesized that cysteamine, an orphan drug for cystinosis, may be a novel therapeutic option for some patients in the future (34). However, clinical trials are required to test the therapeutic safety and efficacy of this approach.

References

01: Ah Mew N, Krivitzky L, McCarter R, et al. Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. J Pediatr 2013;162(2):324-9. PMID 22901741
02: Allan JD, Cusworth DC, Dent CE, et al. A disease, probably hereditary, characterized by severe mental deficiency and a constant gross abnormality of amino acid metabolism. Lancet 1958;1:182-7. PMID 13503250
03: Al-Sayed M, Alahmed S, Alsmadi O, et al. Identification of a common novel mutation in Saudi patients with argininosuccinic aciduria. J Inherit Metab Dis 2005;28(6):877-83. PMID 16435180
04: American College of Medical Genetics. Newborn screening: toward a uniform screening panel and system. Genet Med 2006;8 Suppl 1:1S-252S. PMID 16783161
05: Asai K, Ishii S, Ohta S, Furusho K. Fatal hyperammonaemia in argininosuccinic aciduria following enflurane anaesthesia. Eur J Pediatr 1998;157:169-70. PMID 9504797
06: Bachmann C, Colombo JP. Diagnostic value of orotic acid excretion in heritable disorders of the urea cycle and in hyperammonemia due to organic acidurias. Eur J Pediatr 1980;134:109-13. PMID 7439194
07: Badizadegan K, Perez-Atayde AR. Focal glycogenosis of the liver in disorders of ureagenesis: its occurrence and diagnostic significance. Hepatology 1997;26:365-73. PMID 9252147
08: Balmer C, Pandey AV, Rüfenacht V, et al. Mutations and polymorphisms in the human argininosuccinate lyase (ASL) gene. Hum Mutat 2014;35(1):27-35. PMID 24166829
09: Barbosa P, Cialkowski M, O'Brien WE. Analysis of naturally occurring and site-directed mutations in the argininosuccinate lyase gene. J Biol Chem 1991;266:5286-90. PMID 1705937
10: Baruteau J, Baruteau J, Perocheau DP, et al. Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by Asl gene transfer. Nat Commun 2018; 9(1):3505. PMID 30158522
11: Baruteau J, Jameson E, Morris AA, et al. Expanding the phenotype in argininosuccinic aciduria: need for new therapies. J Inherit Metab Dis 2017;40(3):357-68. PMID 28251416
12: Batshaw ML, Brusilow S, Waber L, et al. Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med 1982;306:1387-92. PMID 7078580
13: Batshaw ML, Robinson MB, Hyland K, Djali S, Heyes MP. Quinolinic acid in children with congenital hyperammonemia. Ann Neurol 1993;34:676-81. PMID 7694541
14: Batshaw ML, Thomas GH, Brusilow SW. New approaches to the diagnosis and treatment of inborn errors of urea synthesis. Pediatrics 1981;68:290-7. PMID 7267240
15: Brunetti-Pierri N, Erez A, Shchelochkov O, Craigen W, Lee B. Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency. Mol Genet Metab 2009;98(1-2):195-7. PMID 19592285
16: Brusilow SW. Arginine, an indispensable amino acid for patients with inborn errors of urea synthesis. J Clin Invest 1984;72:2144. PMID 6511918
17: Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 1991;29:147-50. PMID 2014149
18: Brusilow SW, Batshaw ML. Arginine therapy of argininosuccinase deficiency. Lancet 1979;1(8108):124-7. PMID 84150
19: Brusilow SW, Horwich AL. Urea cycle enzymes. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. 6th edition. New York: McGraw-Hill, 1989:629-63.
20: Burgard P, Kolker S, Haege G, Lindner M, Hoffmann GF. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders – review and meta-analysis of observational studies published over more than 35 years. J Inherit Metab Dis 2016;39(2):219-29. PMID 26634836
21: Butterworth RF. Effects of hyperammonaemia on brain function. J Inherit Metab Dis 1998;21(Suppl):6-20. PMID 9686341
22: Butterworth RF. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis 2007;22(3-4):309-20. PMID 17851742
23: Butterworth RF, Giguere JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Path 1987;6:1-12. PMID 3306479
24: Donn SM, Thoene JG. Prospective prevention of neonatal hyperammonaemia in argininosuccinic aciduria by arginine therapy. J Inherit Metab Dis 1985;8:18-20. PMID 3921755
25: Erez A, Nagamani SC, Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. Am J Med Genet C Semin Med Genet 2011a;157(1):45-53. PMID 21312326
26: Erez A, Nagamani SC, Shchelochkov OA, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med 2011b;17(12):1619-26. PMID 22081021
27: Ficicioglu C, Mandell R, Shih VE. Argininosuccinate lyase deficiency: longterm outcome of 13 patients detected by newborn screening. Mol Genet Metab 2009;98(3):273-7. PMID 19635676
28: Grioni D, Furlan F, Corbetta C, et al. Epilepsy and argininosuccinic aciduria. Neuropediatrics 2011;42(3):97-103. PMID 21744316
29: Haberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis 2012;7:32.** PMID 22642880
30: Hanson C, Hamberger L. Clinical aspects on the use of preimplantation genetic diagnosis in couples at risk. Acta Obstet Gynecol Scand Suppl 1997;164:19-21. PMID 9225629
31: Howell PL, Turner MA, Christodoulou J, et al. Intragenic complementation at the argininosuccinate lyase locus: reconstruction of the active site. J Inherit Metab Dis 1998;21(Suppl 1):72-85. PMID 9686346
32: Hyman SL, Coyle JT, Parke JC, et al. Anorexia and altered serotonin metabolism in a patient with argininosuccinic aciduria. J Pediatr 1986;108:705-9. PMID 2422338
33: Iafolla AK, Gale DS, Roe CR. Citrate therapy in argininosuccinate lyase deficiency. J Pediatr 1990;117:102-5. PMID 2370602
34: Inauen C, Rufenacht V, Pandey AV, et al. Effect of cysteamine on mutant ASL proteins with cysteine for arginine substitutions. Mol Diagn Therap 2016;20(2):125-33. PMID 26745957
35: Kamoun P, Fensom AH, Shin YS, et al. Prenatal diagnosis of the urea cycle diseases: a survey of the European cases. Am J Med Genet 1995;55:247-50. PMID 7717428
36: Kleijer WJ, Garritsen VH, Linnebank M, et al. Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. J Inherit Metab Dis 2002;25(5):399-410. PMID 12408190
37: Kolker S, Cazorla AG, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis 2015a;38(6):1041-57. PMID 25875215
38: Kolker S, Sauer SW, Surtees RA, Leonard JV. The aetiology of neurological complications of organic acidaemias – a role for the blood-brain barrier. J Inherit Metab Dis 2006;29(6):701-4. PMID 17041745
39: Kolker S, Valayannopoulos V, Burlina AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis 2015b;38(6):1059-74. PMID 25875216
40: Kubota K, Ishizaki T. Effect of single oral dose of sodium benzoate on ureagenesis in healthy men and two patients with late onset citrullinaemia. Eur J Clin Pharmacol 1993;45:465-8. PMID 8112377
41: Lerner S, Anderzhanova E, Verbitsky S, et al. ASL metabolically regulates tyrosine hydroxylase in the nucleus locus coeruleus. Cell Rep 2019;29(8):2144-53. PMID 31747589
42: Lerner S, Eilam R, Adler L, et al. ASL expression in ALDH1A1 + neurons in the substantia nigra metabolically contributes to neurodegenerative phenotype. Hum Genet 2021;140(10):1471-85. PMID 34417872
43: Lewis PD, Miller AL. Argininosuccinic aciduria. Case report with neuropathologic findings. Brain 1970;93:413-22. PMID 5422414
44: Lichter-Konecki U. Profiling of astrocyte properties in the hyperammonemic brain: shedding new light on the pathophysiology of the brain damage in hyperammonemia. J Inherit Metab Dis 2008;31(4):492-502. PMID 18683079
45: Lichter-Konecki U, Mangin JM, Gordish-Dressman H, Hoffman EP, Gallo V. Gene expression profiling of astrocytes from hyperammonemic mice reveals altered pathways for water and potassium homeostasis in vivo. Glia 2008;56(4):365-77. PMID 18186079
46: Linnebank M, Tschiedel E, Haberle J, et al. Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene. Hum Genet 2002;111(4-5):350-9. PMID 12384776
47: Maestri NE, Hauser ER, Bartholomew D, Brusilow SW. Prospective treatment of urea cycle disorders. J Pediatr 1991;119:923-8. PMID 1720458
48: Maestri NE, McGowan KD, Brusilow SW. Plasma glutamine concentration: a guide in the management of urea cycle disorders. J Pediatr 1992;121:259-61. PMID 1640294
49: Mandell R, Packman S, Laframboise R, et al. Use of amniotic fluid amino acids in prenatal testing for argininosuccinic aciduria and citrullinaemia. Prenat Diagn 1996;16:419-24. PMID 8843999
50: Marble M, McGoey RR, Mannick E, et al. Living related liver transplant in a patient with argininosuccinic aciduria and cirrhosis: metabolic follow-up. J Pediatr Gastroenterol Nutr 2008;46(4):453-6. PMID 18367960
51: Mardach MR, Roe K, Cederbaum SD. Successful pregnancy outcome in a woman with argininosuccinate lyase deficiency. J Inherit Metab Dis 1999;22:102-6. PMID 10234604
52: Mercimek-Mahmutoglu S, Moeslinger D, Häberle J, et al. Long-term outcome of patients with argininosuccinate lyase deficiency diagnosed by newborn screening in Austria. Mol Genet Metab 2010;100(1):24-8. PMID 20236848
53: Michalak A, Butterworth RF. Ornithine transcarbamylase deficiency: pathogenesis of the cerebral disorder and new prospects for therapy. Metab Brain Dis 1997;12:171-82. PMID 9346466
54: Morgan HB, Swaiman KF, Johnson BD. Diagnosis of argininosuccinic aciduria after valproic acid-induced hyperammonemia. Neurology 1987;37:886-7. PMID 3106853
55: Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome in children with inborn errors of urea synthesis. N Engl J Med 1984;310:1500-5. PMID 6717540
56: Nagamani SC, Campeau PM, Shchelochkov OA, et al. Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. Am J Hum Genet 2012a;90(5):836-46. PMID 22541557
57: Nagamani SC, Shchelochkov OA, Mullins MA, et al. Randomized Controlled Trial to Evaluate the Effects of High-Dose versus Low-Dose of Arginine Therapy on Hepatic Dysfunction in Argininosuccinic Aciduria. Mol Genet Metab 2012b;107(3):315-21. PMID 23040521
58: Naylor SL, Klebe RJ, Shows TB. Argininosuccinic aciduria: assignment of the argininosuccinate lyase gene to the pter to q22 region of human chromosome 7 by bioautography. Proc Natl Acad Sci U S A 1978;75:6159-62. PMID 282632
59: Newnham T, Hardikar W, Allen K, et al. Liver transplantation for argininosuccinic aciduria: clinical, biochemical, and metabolic outcome. Liver Transpl 2008;14(1):41-5. PMID 18161830
60: Norenberg MD, Jayakumar AR, Rama Rao KV, Panickar KS. New concepts in the mechanism of ammonia-induced astrocyte swelling. Metab Brain Dis 2007;22(3-4):219-34. PMID 17823859
61: Posset R, Garcia-Cazorla A, Valayannopoulos V, et al. Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders. J Inherit Metab Dis 2016;39(5):661-72. PMID 27106216
62: Posset R, Kölker S, Gleich F, et al. Severity-adjusted evaluation of newborn screening on the metabolic disease course in individuals with cytosolic urea cycle disorders. Mol Genet Metab 2020;131(4):390-7. PMID 33288448
63: Probst J, Kölker S, Okun JG, et al. Chronic hyperammonemia causes a hypoglutamatergic and hyperGABAergic metabolic state associated with neurobehavioral abnormalities in zebrafish larvae. Exp Neurol 2020;331:113330. PMID 32339612
64: Reid Sutton V, Pan Y, Davis EC, Craigen WJ. A mouse model of argininosuccinic aciduria: biochemical characterization. Mol Genet Metab 2003;78(1):11-6. PMID 12559843
65: Renner C, Sewell AC, Bervoets K, et al. Sodium citrate supplementation in inborn argininosuccinate lyase deficiency: a study in a 5-year-old patient under total parenteral nutrition. Eur J Pediatr 1995;154:909-14. PMID 8582405
66: Scaglia F, Brunetti-Pierri N, Kleppe S, et al. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. J Nutr 2004;134(10 Suppl):2775S-2782S. PMID 15465784
67: Schmidt J, Kroeber S, Irouschek A, Birkholz T, Schroth M, Albrecht S. Anesthetic management of patients with ornithine transcarbamylase deficiency. Paediatr Anaesth 2006;16(3):333-7. PMID 16490102
68: Schutgens RB, Beemer FA, Tegelaers WH, et al. Mild variant of argininosuccinic aciduria. J Inherit Metab Dis 1980;2:13-4. PMID 6796754
69: Shih VE. Hereditary urea-cycle disorders. In: Grisolia S, Baguena R, Mayor F, editors. The urea cycle. New York: Wiley, 1976:367-414.
70: Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab 2013;110(1-2):179-80. PMID 23972786
71: Todd S, McGill JR, McCombs JL, Moore CM, Weider I, Naylor SL. cDNA sequence, interspecies comparison, and gene mapping analysis of argininosuccinate lyase. Genomics 1989;4:53-9. PMID 2644168
72: Trevisson E, Salviati L, Baldoin MC, et al. Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novel ASL pseudogene. Hum Mutat 2007;28(7):694-702. PMID 17326097
73: Uchino T, Endo F, Matsuda I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis 1998;21(Suppl):151-9. PMID 9686352
74: Verma NP, Hart ZH, Kooi KA. Electroencephalographic findings in urea-cycle disorders. Electroencephalogr Clin Neurophysiol 1984;57:105-12. PMID 6198150
75: Walker DC, McCloskey DA, Simard, LR, et al. Molecular analysis of human argininosuccinate lyase: mutant characterization and alternative splicing of the coding region. Proc Natl Acad Sci U S A 1990;87:9625-9. PMID 2263616
76: Watanabe A, Sekizawa A, Taguchi A, et al. Prenatal diagnosis of ornithine transcarbamylase deficiency by using a single nucleated erythrocyte from maternal blood. Hum Genet 1998;102:611-5. PMID 9703419
77: Whitington PF, Alonso EM, Boyle JT, et al. Liver transplantation for the treatment of urea cycle disorders. J Inherit Metab Dis 1998;21:112-8. PMID 9686349
78: Widhalm K, Koch S, Schreibenreiter S, et al. Long-term follow-up of 12 patients with the late-onset variant of argininosuccinic acid lyase deficiency: no impairment of intellectual and psychomotor development during therapy. Pediatrics 1992;89(6 Pt 2):1182-4. PMID 1594374
79: Worthington S, Christodoulou J, Wilcken B, et al. Pregnancy and argininosuccinic aciduria. J Inherit Metab Dis 1996;19:621-3. PMID 8892017
80: Yu B, Thompson GD, Yip P, Howell PL, Davidson AR. Mechanisms for intragenic complementation at the human argininosuccinate lyase locus. Biochemistry 2001;40(51):15581-90. PMID 11747433
81: Zielonka M, Breuer M, Okun JG, Carl M, Friedrich H, Kolker S. Pharmacologic rescue of hyperammonemia-induced toxicity in zebrafish by inhibition of ornithine aminotransferase. PLoS One 2018;13(9):e0203707. PMID 30199544
82: Zielonka M, Garbade SF, Gleich F, et al. From genotype to phenotype: early prediction of disease severity in argininosuccinic aciduria. Hum Mutat 2020;41(5):946-60. PMID 31943503
83: Zielonka M, Probst J, Carl M, Hoffmann GF, Kolker S, Okun JG. Bioenergetic dysfunction in a zebrafish model of acute hyperammonemic decompensation. Exp Neurol 2019;314:91-9. PMID 30653968
84: Zimmerman A, Bachmann C, Baumgartner R. Severe liver fibrosis in argininosuccinic aciduria. Arch Pathol Lab Med 1986;110:136-40. PMID 3753845
85: Zwingmann C, Chatauret N, Rose C, Leibfritz D, Butterworth RF. Selective alterations of brain osmolytes in acute liver failure: protective effect of mild hypothermia. Brain Res 2004;999(1):118-23. PMID 14746928

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Stefan Kolker MD

Dr. Kolker of the Center of Pediatrics and Adolescent Medicine, University Hospital Heidelberg has no relevant financial relationships to disclose.
See Profile
Matthias Zielonka MD

Dr. Zielonka of University Children’s Hospital Heidelberg has no relevant financial relationships to disclose.
See Profile

Editor

Barry Wolf MD PhD

Dr. Wolf of Lurie Children's Hospital of Chicago has no relevant financial relationships to disclose.
See Profile

Former Authors

Mendel Tuchman MD and Mark L Batshaw MD

Patient Profile

Age range of presentation: 0 month to 18 years
Sex preponderance: male=female
Heredity: heredity typical

autosomal recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Disorders of urea cycle metabolism: 270.6
ICD-10: Disorders of urea cycle metabolism: E72.2
OMIM: Argininosuccinic aciduria: #207900

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Argininosuccinic acidemia

Associated Disorders

Cerebral palsy
Mental retardation
Seizure disorder
Visual deficits

Differential Diagnosis

other inborn errors of metabolism
other urea cycle disorders
amino acidopathies
congenital lactic acidoses
defects in fatty acid oxidation
- organic acidurias
- transient hyperammonemia of the newborn
- sepsis
- intracranial hemorrhage
- cardiorespiratory disorders
- liver disease
- Reye syndrome
- drug toxicity
- hepatotoxins

Also Relevant

Carbamoyl phosphate synthetase 1 deficiency
Citrullinemias types 1 and 2
Hyperargininemia
N-acetylglutamate synthase deficiency
Ornithine transcarbamylase deficiency
- Screening of newborns for neurogenetic abnormalities

Clinical Categories

Neurogenetic Disorders

Web References

Guidelines

NORD: Urea cycle disorders

Argininosuccinic acidemia

Argininosuccinic acidemia

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hypermethioninemia

Multiple acyl-CoA dehydrogenase deficiency

Medium-chain acyl-CoA dehydrogenase deficiency

Long-chain fatty acid oxidation defects

Nonketotic hyperglycinemia

Leukodystrophies

Mucopolysaccharidoses

Alexander disease

Argininosuccinic acidemia

Introduction

Overview

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hypermethioninemia

Multiple acyl-CoA dehydrogenase deficiency

Medium-chain acyl-CoA dehydrogenase deficiency

Long-chain fatty acid oxidation defects

Nonketotic hyperglycinemia

Leukodystrophies

Mucopolysaccharidoses

Alexander disease

This is an article preview.
Start a Free Account
to access the full version.